Salute e Benessere

Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing…

Eviva and POH are grounded in three principles: Eviva and POH are grounded in three principles: On Sunday,MSNBC published an op-edby Morozov, leading vaccinologist Dr.Helen Petousis-Harrisand Eviva board member ProfessorStephan Lewandowsky. " Robert F. Kennedy Jr.and others … appear to be orchestrating a strategic attack on aluminum-containing vaccines," the op-ed says. But the science does not support aluminum as the culprit. In a major newstudyinvolving more than 1...
PR Newswire
30/07/2025

Spineway : H1 2025 results - Continued improvement in results and financial…

Press release Ecully, July 30, 2025 – 7 p.m. SPINEWAYH1 2025 results Continued improvement in results and financial positionFull-year 2025 growth target confirmedIn thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535 Cost of sales(1,702)(2,059) Gross margin% of revenue3,87069%4,47668% Net operating expenses Of which general operating costs (5,068) ...
Nasdaq GlobeNewswire
30/07/2025

Global Market for Thyroid Gland Disorders Surges Amid Breakthroughs in…

This report provides a thorough overview of the global market for thyroid gland disorder diagnostics and treatments. It segments the market by disease type (such as hypothyroidism, hyperthyroidism, and thyroid cancer), as well as by product type, including diagnostics (blood tests, imaging, and procedures) and treatments (medications, surgeries, and therapies for thyroid eye disease). It also analyzes market distribution across end users like hospitals, clinics, pharmacies, research…
PR Newswire
30/07/2025

Oxurion Receives Amended Transparency Notification from Atlas Special…

Leuven, BELGIUM – July 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 29, 2025, from Atlas Special…
Actusnews Wire
30/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential…
Actusnews Wire
30/07/2025

Remote Patient Monitoring Market to Grow at a CAGR of 19.0% from 2025 to 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/remote-patient-monitoring-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/remote-patient-monitoring-market Remote Patient Monitoring Market Key Growth Drivers Remote monitoring of patients has benefitted in obtaining real-time patient data for illnesses, such as chronic obstructive pulmonary disease (COPD), cancer, or diabetes, resulting in timely management of the diseases. Implementation...
PR Newswire
30/07/2025

Biosimilars Market is Estimated to Reach USD 88.9 Billion by 2032 | SkyQuest…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/biosimilars-market Get a Free Sample Report - https://www.skyquestt.com/sample-request/biosimilars-market Biosimilars Market Key Growth Drivers: The growing burden of rising obesity rates, poor diets, and chronic physical inactivity has compelled many healthcare systems to look for different ways to provide patients with affordable treatments. According to WHO estimates, being overweight or obese will cause more...
PR Newswire
30/07/2025

Dental Imaging Market Worth US$4.69 billion by 2030 with 7.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=109621591 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=109621591 Browse in-depth TOC on "Dental Imaging Market" 150 - Tables 45 - Figures 250 - Pages By product,the dental imaging market has been divided into two main categories: extraoral and intraoral imaging systems. Among the extraoral imaging systems segment, panoramic imaging systems represented the...
PR Newswire
30/07/2025

Egg Medical Announces U.S. Patent and Trademark Office Issues Final Rejection of…

"The remarkable part of this lawsuit is that Egg Medical never sold any product that fell within the scope of Rampart's now-rejected patent claims," said Robert F. Wilson, MD, CEO of Egg Medical. "Egg Medical respects prior intellectual property. The USPTO rejecting the claims in Rampart's asserted '056 patent validates what we have been saying all along." "The remarkable part of this lawsuit is that Egg Medical never sold any product that fell within the scope of…
PR Newswire
30/07/2025

C-Parts Market to reach USD 212.79 billion by 2031, due to an Increase in Orders…

The c-parts market outlook remains positive, as it is well-positioned to serve the requirements of end-user industries such as construction, aerospace & defense, oil & gas, agriculture, and manufacturing. Manufacturers are under constant pressure to maintain the overall operational costs while improving efficiency. Thus, the demand for durable and high-strength industrial components is increasing to avoid additional operational costs, machinery downtime, and stricter industrial norms…
PR Newswire
30/07/2025

Biosensors Market Set to Reach Valuation of US$ 75.84 Billion By 2033 | New Wave…

Request PDF Sample Pages: https://www.astuteanalytica.com/request-sample/biosensors-market Request PDF Sample Pages:https://www.astuteanalytica.com/request-sample/biosensors-market Advanced wearables now incorporate a wider array of sensors, tracking biometrics like EMG, EEG, ECG, heart rate, blood pressure, and temperature. A major frontier in the biosensors market is non-invasive glucose monitoring. One novel optical device using 660 nm light achieved a Mean Absolute Relative...
PR Newswire
30/07/2025

Emerald Clinical Trials Confirms CEO Transition and Continuity Plan

"We thank Mary for her contributions," said Sean Carney, Chair of the Board. "Emerald Clinical Trials is a leading CRO with global capabilities and with Glenn stepping in as Interim CEO, we are confident in our ability to maintain momentum and deliver for our clients," Sean Carney said. "We thank Mary for her contributions," saidSean Carney, Chair of the Board. "Emerald Clinical Trials is a leading CRO with global capabilities and with Glenn stepping in as…
PR Newswire
30/07/2025

MAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of…

MAGENTIQ EYE's FDA- and CE-approved software, MAGENTIQ-COLO™, enhances polyp detection and analysis capabilities during colonoscopies, significantly improving adenoma detection rates. MAGENTIQ-COLO also offers real-time insights, and its CE-approved version includes polyp-size category and type estimation, and advanced AI-generated reports. MAGENTIQ EYE's FDA- and CE-approved software,MAGENTIQ-COLO™, enhances polyp detection and analysis capabilities during colonoscopies, significantly...
PR Newswire
30/07/2025

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025…

On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10 thconsecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues.Innovative portfolio continues to fuel strong growth and provide value to diverse and critical patient...
Nasdaq GlobeNewswire
30/07/2025

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS…

The findings highlight the potential of food assistance programs to support cognitive health in the aging population and point to the need for additional efforts to reduce disparities in cognitive aging across different racial and ethnic groups, the researchers said. They also underscore the need for public health policies that ensure equitable access to programs like SNAP, which helps low-income individuals and families buy food, particularly for populations that may face additional barriers to…
PR Newswire
30/07/2025

KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy

The procedure was led by Dr. Khalid Aldaghri, Consultant in bariatric, upper gastrointestinal, and robotic surgery at KFSHRC. Utilizing the Ivor Lewis technique, a complex and technically demanding procedure involving two phases. The abdominal phase involved stomach mobilization and creation of a gastric conduit. This was followed by the thoracic phase, in which the diseased esophagus was resected and the conduit is robotically connected within the chest.Precision in the robotic system...
Nasdaq GlobeNewswire
30/07/2025

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic…

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, Allianthera (Suzhou) Biopharmaceuticals Co., Ltd., and its affiliate Allianthera Boston, Inc., a clinical stage...
Nasdaq GlobeNewswire
30/07/2025

Leading European Shipbuilder Selects Aino’s SaaS Platform

Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the customer’s proactive work ability management and employee well-being initiatives. “We are proud that our platform will support this organization in improving work ability and reducing health-related risks across their operations,” says Jyrki Eklund, CEO of Aino Health. Through the...
Nasdaq GlobeNewswire
30/07/2025

Casino Group: Release of the H1 2025 presentation

RELEASE OF THE HALF YEAR 2025RESULTS PRESENTATION The Group has released its half year 2025 results presentation on its website. It is available at this link: https://www.groupe-casino.fr/wp-content/uploads/2025/07/2025-07-30-H1-2025-Results-Presentation.pdfAnalyst and investor contactsCharlotte Izabel +33 (0)6 89 19 88 33 cizabel@groupe-casino.frInvestor Relations +33 (0)1 53 65 24 17IR_Casino@groupe-casino.fr Press contactsCorporate...
Nasdaq GlobeNewswire
30/07/2025

Casino Group: Q2 SALES AND H1 2025 RESULTS

Q2 SALES AND H1 2025 RESULTS The New Casino: an improving first half-yearGrowth in net sales: +2.4% LFL in Q2 and +0.5% in H1 Supported by a more favourable market environment in Q2 and the initial results of its “Renouveau 2028” strategic plan, the Group is back to growth for the first time since its financial restructuring, with a second-quarter rise across all convenience brands.Roll out of the newstore concepts 32 Franprix stores remodelled with the ‘ Oxygène ’ concept...
Nasdaq GlobeNewswire
30/07/2025

AB Science receives regulatory approval from European countries to initiate…

PRESS RELEASEAB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIATHE COMBINATION OF AB8939 TARGETING MICROTUBULE AND STEM CELLS AND VENETOCLAX TARGETING BCL-2 SHOWS POTENTIAL SYNERGISTIC EFFICACY AND GOOD HEMATOLOGICAL TOLERANCE COMPARED WITH STANDARD OF CARE CHEMOTHERAPIES, IN PARTICULAR IN THE POOR RESPONDERS TO STANDARD OF CARE...
Nasdaq GlobeNewswire
30/07/2025

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec…

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEProposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibilitySandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France,...
Nasdaq GlobeNewswire
30/07/2025

Photocure ASA: Results for the second quarter of 2025

The company continued to execute on its plan to expand blue light cystoscopy use in Q2 2025 with the installation of 12 new Saphira™ towers in the U.S. — 3 new accounts and 9 blue light tower upgrades. With the increasing momentum provided by ForTec's mobile solution, Photocure had 359 active accounts in the U.S. at the end of the quarter, an increase of 24% versus the second quarter of 2024. The company continued to execute on its plan to expand blue light cystoscopy use in Q2 2025 with the...
PR Newswire
30/07/2025

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1…

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, largely driven by sales in Europe. NDA approval with Simcere in China.Aprocitentan (TRYVIO/JERAYGO) commercial opportunity significantly improved with REMS removal and very positive real-world experience – engaging in partnership discussions.Net revenue H1 2025 of CHF 131...
Nasdaq GlobeNewswire
30/07/2025
Altri  Comunicati